Protara Therapeutics, Inc.
- Open
- 3.77
- Day high
- 3.88
- Day low
- 3.71
- Prev close
- 3.82
- Volume
- 506K
- Mkt cap
- $228M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.4
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$882K over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions accumulating (13F)
Protara Therapeutics, Inc. (TARA) is a Healthcare company listed on NASDAQ. The stock is up 19% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4).
Protara Therapeutics, Inc. (TARA) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TARA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 11, 2026 | $-0.33 | $-0.36 | -10.5% | — | — |
| May 19, 2026 | $-0.36 | $-0.31 | +13.9% | — | — |
| Mar 10, 2026 | $-0.31 | $-0.38 | -20.7% | — | — |
| May 8, 2025 | $-0.47 | $-0.29 | +38.3% | — | — |
| Mar 5, 2025 | $-0.57 | $-0.48 | +15.8% | — | — |
| May 2, 2024 | $-0.99 | $-0.97 | +2.0% | — | — |
| Mar 13, 2024 | $-1.03 | $-0.90 | +12.6% | $1M | — |
| Nov 3, 2023 | $-1.10 | $-0.87 | +20.9% | — | — |
| Aug 3, 2023 | $-0.97 | $-1.00 | -3.1% | — | — |
| May 4, 2023 | $-1.00 | $-0.80 | +20.0% | — | — |
| Mar 8, 2023 | $-0.77 | $-0.84 | -9.1% | — | — |
| Nov 3, 2022 | $-0.85 | $-0.68 | +20.0% | — | — |
TARA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | Shefferman Jessedirector, officer: CEO and President | Sell | 215,687 | $4.09 |
| Jul 1, 2026 | Shefferman Jessedirector, officer: CEO and President | Option | 215,687 | $1.91 |
| Jun 16, 2026 | BESHAR LUKE Mdirector | Grant | 31,000 | $3.94 |
| Jun 16, 2026 | Flannelly Barry Pdirector | Grant | 31,000 | $3.94 |
| Jun 16, 2026 | Smith Cynthiadirector | Grant | 31,000 | $3.94 |
| Jun 16, 2026 | GARCEAU ROGERdirector | Grant | 31,000 | $3.94 |
| Jun 16, 2026 | Huang Janedirector | Grant | 31,000 | $3.94 |
| Jun 16, 2026 | SARGEN GREGORYdirector | Grant | 31,000 | $3.94 |
| Jun 16, 2026 | Solomon Michael Edwarddirector | Grant | 31,000 | $3.94 |
| Jun 16, 2026 | Levy Richard Sdirector | Grant | 31,000 | $3.94 |
| Apr 9, 2026 | Zummo Jacquelineofficer: Chief R&D Officer | Sell | 1,134 | $5.40 |
| Apr 2, 2026 | Zummo Jacquelineofficer: Chief R&D Officer | Sell | 22,598 | $5.26 |
| Jan 27, 2026 | Shefferman Jessedirector, officer: CEO and President | Tax | 8,732 | $6.67 |
| Jan 27, 2026 | Fabbio Patrickofficer: Chief Financial Officer | Tax | 3,261 | $6.67 |
| Jan 27, 2026 | Fry Hannahofficer: VP, Controller | Tax | 1,457 | $6.67 |
Source: TARA SEC Form 4 filings, latest Jul 1, 2026. For informational purposes only — not investment advice.
See the full TARA insider & 13F page →Protara Therapeutics, Inc. company profile
Overview
Protara Therapeutics, Inc. (NASDAQ:TARA) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. Originally incorporated as ArTara Therapeutics, Inc., the company changed its name to Protara Therapeutics in May 2020. The company focuses on identifying and advancing transformative therapies for the treatment of cancer and rare diseases, with a particular emphasis on developing innovative cell therapies and substrate replacement treatments for underserved patient populations.
Business
Protara Therapeutics operates in the biotechnology sector, specifically focusing on developing treatments for cancer and rare diseases. The company's business centers around two primary therapeutic programs that address significant unmet medical needs. The company's lead program is TARA-002, an investigational cell therapy designed to treat lymphatic malformations. Lymphatic malformations are rare, benign vascular lesions that occur when lymphatic vessels fail to develop properly during embryonic development. These malformations can cause significant morbidity, including disfigurement, functional impairment, and complications such as infections or bleeding. TARA-002 represents a novel approach using cellular therapy to address these challenging conditions where traditional treatment options are limited. The second major program involves intravenous choline chloride, an investigational phospholipid substrate replacement therapy. This treatment targets intestinal failure-associated liver disease (IFALD), a serious complication that can develop in patients with short bowel syndrome or other conditions requiring long-term parenteral nutrition. IFALD occurs when the liver becomes damaged due to prolonged reliance on intravenous nutrition, and choline chloride aims to provide essential nutrients that may help prevent or treat this liver dysfunction. Both programs represent the company's focus on rare disease therapeutics, where there are often few or no approved treatment options available to patients. As a clinical-stage company, Protara does not yet generate revenue from product sales, instead focusing its resources on advancing these investigational therapies through clinical trials toward potential regulatory approval.
Revenue model
As a clinical-stage biopharmaceutical company, Protara Therapeutics does not currently generate revenue from product sales. The company operates on a research and development model typical of early-stage biotech firms, funding its operations through equity financing, grants, and potential partnership agreements. The company's future revenue model will depend on successfully advancing its therapeutic candidates through clinical trials and obtaining regulatory approval. Once approved, TARA-002 and intravenous choline chloride would generate revenue through direct sales to hospitals, specialty clinics, and healthcare providers treating patients with lymphatic malformations and intestinal failure-associated liver disease, respectively. Several factors could significantly impact the company's future profitability and margins. Regulatory approval timelines represent the primary risk, as delays in clinical trials or regulatory setbacks could extend the time to market and increase development costs. Competition from alternative therapies or new treatment modalities could affect pricing power and market share. Manufacturing and supply chain costs will be critical, particularly for TARA-002 as a cell therapy, which typically involves complex and expensive production processes. Market size limitations present both opportunities and challenges, as rare disease treatments often command premium pricing due to limited patient populations, but this also constrains total addressable market size. Reimbursement and payer acceptance will be crucial for commercial success, as healthcare systems increasingly scrutinize the cost-effectiveness of new therapies, particularly in rare disease areas where treatment costs can be substantial.
Competitive moat
Protara Therapeutics currently operates with limited competitive moats, which is typical for clinical-stage biotechnology companies. The company's primary potential advantages lie in its intellectual property portfolio surrounding TARA-002 and intravenous choline chloride, though the strength and breadth of these patents are not extensively detailed in available information. The company benefits from first-mover advantages in addressing specific rare disease indications where few treatment options exist. For lymphatic malformations, current treatment approaches are largely surgical or involve sclerotherapy, making TARA-002's cellular therapy approach potentially differentiated. Similarly, for intestinal failure-associated liver disease, the specific formulation and delivery method of intravenous choline chloride may provide competitive positioning. However, the company faces significant competitive vulnerabilities. Large pharmaceutical companies with substantially greater resources could develop competing therapies or acquire smaller competitors with similar approaches. The regulatory approval process creates uncertainty, as clinical trial failures could eliminate the company's competitive position entirely. Additionally, alternative treatment modalities being developed by other companies, including gene therapies, other cell therapies, or novel small molecule approaches, could potentially address the same patient populations with superior efficacy or safety profiles. The rare disease focus provides some protection from broad competition, as these markets are often too small to attract multiple large players. However, this same factor limits the overall market opportunity and makes the company vulnerable to single-product risk, particularly given its concentrated pipeline of just two main programs.
Risks & safety
Protara Therapeutics maintains a relatively strong financial position despite ongoing losses, though typical risks associated with clinical-stage biotechnology companies remain present. • Cash position: Strong liquidity with $91.5 million in cash and short-term investments as of Q1 2025, providing substantial runway for operations • Debt levels: Minimal debt burden with debt-to-equity ratio of only 0.027, indicating low financial leverage • Current ratio: Excellent short-term liquidity at 18.0x, demonstrating ability to meet near-term obligations • Cash burn: Operating cash flow negative at $14.7 million in Q1 2025, suggesting approximately 6+ quarters of runway at current burn rate • Valuation metrics: Trading at 1.1x price-to-book ratio and negative P/E due to losses, with Graham net-net working capital value of 2.8x current price • Revenue generation: Zero current revenue creates dependency on financing and clinical success for long-term viability • Clinical risk: Single-point-of-failure risk if key programs fail in clinical trials, with limited pipeline diversification
Recent development
Based on available financial data, Protara Therapeutics has maintained focus on advancing its two core therapeutic programs while managing cash resources efficiently. The company significantly strengthened its balance sheet during 2024, with cash and short-term investments increasing from approximately $40 million at the end of 2023 to $163 million by year-end 2024, indicating successful fundraising activities. The company has demonstrated disciplined cash management, with quarterly operating cash burn remaining relatively stable in the $7-15 million range throughout 2024. This suggests controlled spending on clinical development activities while maintaining sufficient resources to advance both TARA-002 and intravenous choline chloride programs. The absence of revenue generation continues to reflect the company's pre-commercial status, with all financial resources dedicated to research and development activities. The substantial increase in cash reserves during 2024 positions the company to potentially accelerate clinical development timelines or expand its pipeline through additional programs or partnerships. While specific clinical milestones and program updates are not detailed in the available financial summaries, the company's maintained focus on its core therapeutic areas and improved financial position suggest continued commitment to advancing both programs toward potential regulatory approval and commercialization.
TARA company profile · for informational purposes only — not investment advice.
Track TARA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free